2017.12.01
I-Mab Biopharma (I-Mab) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.
2017.03.22
With all our efforts, Third Venture Biopharma's official website (in Chinese) was officially in public test phase on 21 March 2017. We hope that we can serve for our clients in a more prudent and professional manner. TVB will consistently move forward responsible for our staff and various clients.
2017.03.21
March 21st, 2017, Tianjin, China – Third Venture Biopharma, a company focusing on the discovery and development of the innovative biologics, and Tasgen Biotech, a clinical stage biologics development company focused on half-life extension bio-betters
2016.12.23
On 19 December 2016, Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals, under which, Third Venture Biopharma was granted the exclusive rights to develop and commercialize Olamkicept (an autoimmune drug of Ferring Pharmaceuticals) for autoimmune indications in Asia